Clinical Trials Logo

Adenocarcinoma clinical trials

View clinical trials related to Adenocarcinoma.

Filter by:

NCT ID: NCT03921021 Recruiting - Clinical trials for Esophagogastric Adenocarcinoma

Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Start date: April 25, 2019
Phase: Phase 2
Study type: Interventional

This is a phase II study of OBP-301 with pembrolizumab in advanced gastric and gastroesophageal junction adenocarcinoma that has progressed on at least 2 lines of prior therapy for advanced disease.

NCT ID: NCT03918499 Not yet recruiting - Clinical trials for Stage IV Gastroesophageal Junction Adenocarcinoma

IRX-2, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer

Start date: June 24, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib/II trial studies the side effects of IRX-2, cyclophosphamide, and pembrolizumab work in treating participants with gastric or gastroesophageal junction cancer that has come back or that has spread to other places in the body. Interleukins, such as those found in IRX-2, are proteins made by white blood cells and other cells in the body and may help regulate immune response. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as pembrolizumab, interfere with the ability of tumor cells to grow and spread. Giving RX-2, cyclophosphamide, and pembrolizumab may work better in treating participants with gastric or gastroesophageal junction cancer.

NCT ID: NCT03915444 Not yet recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma

Start date: April 15, 2019
Phase: Phase 2
Study type: Interventional

This is a phase II open-label study evaluating the efficacy and safety of nab-paclitaxel cisplatin, and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.

NCT ID: NCT03914612 Not yet recruiting - Clinical trials for Endometrial Serous Adenocarcinoma

Pembrolizumab in Addition to Paclitaxel and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Start date: April 26, 2019
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well pembrolizumab, in addition to paclitaxel and carboplatin, works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab, paclitaxel, and carboplatin together may work better in treating patients with endometrial cancer compared to giving only paclitaxel and carboplatin.

NCT ID: NCT03912818 Recruiting - Clinical trials for Bladder Urothelial Carcinoma

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Start date: April 10, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of durvalumab and chemotherapy before surgery in treating patients with variant histology bladder cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, vinblastine, doxorubicin, cisplatin, gemcitabine, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving durvalumab in addition to standard chemotherapy may lead to better outcomes in patients with variant histology bladder cancer.

NCT ID: NCT03910387 Not yet recruiting - Clinical trials for Metastatic Pancreatic Adenocarcinoma

Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

Start date: April 1, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well telotristat ethyl works in promoting weight stability in patients with pancreatic adenocarcinoma that has come back and spread to other places in the body. Telotristat ethyl may decrease bowel movements which may make patients gain weight. Stabilizing weight may help patients tolerate chemotherapy better and improve longevity.

NCT ID: NCT03908333 Not yet recruiting - Pancreatic Cancer Clinical Trials

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Start date: May 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to see if a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer. Vitamin C is a nutrient found in food and dietary supplements. It protects cells and also plays a key role in making collagen (which provides strength and structure to skin, bones, tissues and tendons). High-dose vitamin C may be given by intravenous (IV) infusion (through a vein into the bloodstream) or orally (taken by mouth). When taken by intravenous infusion, vitamin C can reach much higher levels in the blood than when the same amount is taken by mouth. Some human studies of high-dose IV vitamin C in patients with cancer have shown improved quality of life, as well as improvements in physical, mental, and emotional functions, symptoms of fatigue, nausea and vomiting, pain, and appetite loss. Intravenous high-dose ascorbic acid has caused very few side effects in clinical trials.

NCT ID: NCT03905317 Recruiting - Lung Adenocarcinoma Clinical Trials

Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene

Start date: March 1, 2019
Phase: Phase 2
Study type: Interventional

This prospective phase II study is determined to explore the efficacy and safety of radiotherapy and bevacizumab maintenance therapy for oligometastatic lung adenocarcinoma with negative driver genes

NCT ID: NCT03904563 Recruiting - Lung Adenocarcinoma Clinical Trials

Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma

Start date: January 1, 2019
Phase: Phase 2
Study type: Interventional

This prospective phase II study is to determine the efficacy and safety of bevacizumab maintenance therapy after concurrent chemoradiotherapy in locally advanced lung adenocarcinoma

NCT ID: NCT03904043 Not yet recruiting - Clinical trials for Adenocarcinoma of the Lower Rectum

Non-Operative Management and Early Response Assessment in Rectal Cancer

NOM-ERA
Start date: June 30, 2019
Phase: N/A
Study type: Interventional

The investigators' preliminary data from a phase I pilot study of short course radiation therapy followed by chemotherapy showed nearly 80% complete clinical response (cCR) (final analysis still pending). Given the promising response rate, the investigators are evaluating short course total neoadjuvant therapy (SC-TNT) in a multi-institution phase II trial to validate the cCR rate of this treatment paradigm.